• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival.

作者信息

Jullien Maxime, Le Bourgeois Amandine, Peterlin Pierre, Garnier Alice, Guillaume Thierry, Béné Marie C, Chevallier Patrice

机构信息

Hematology Department, Nantes University Hospital, Nantes, France.

INSERM UMR1232, CRCINA IRS-UN, University of Nantes, Nantes, France.

出版信息

Bone Marrow Transplant. 2023 Jun;58(6):723-726. doi: 10.1038/s41409-023-01956-y. Epub 2023 Mar 23.

DOI:10.1038/s41409-023-01956-y
PMID:36959369
Abstract
摘要

相似文献

1
Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival.在非清髓性外周血单倍体相合移植中加入抗胸腺细胞球蛋白（ATG）并联合移植后环磷酰胺（PTCY）可降低急性移植物抗宿主病（GVHD）发生率，并改善无GVHD复发的生存率。
Bone Marrow Transplant. 2023 Jun;58(6):723-726. doi: 10.1038/s41409-023-01956-y. Epub 2023 Mar 23.
2
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.低剂量移植后环磷酰胺联合低剂量移植后抗胸腺细胞球蛋白用于单倍体相合外周血干细胞移植中预防移植物抗宿主病：一项多中心随机对照临床试验，预处理方案为氟达拉滨-白消安-阿糖胞苷
Br J Haematol. 2023 Jan;200(2):210-221. doi: 10.1111/bjh.18483. Epub 2022 Oct 6.
3
Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia.与标准抗胸腺细胞球蛋白（ATG）方案相比，在急性白血病的单倍体外周血造血干细胞移植中，抗胸腺细胞球蛋白（ATG）与移植后环磷酰胺（PTCy）的改良联合方案。
Front Immunol. 2022 Aug 5;13:921293. doi: 10.3389/fimmu.2022.921293. eCollection 2022.
4
Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.异基因造血细胞移植治疗高危急性髓系白血病和骨髓增生异常综合征中，移植后环磷酰胺联合抗胸腺细胞球蛋白作为移植物抗宿主病预防。
Acta Haematol. 2021;144(1):66-73. doi: 10.1159/000507536. Epub 2020 May 19.
5
Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.氟达拉滨和抗胸腺细胞球蛋白预处理方案联合移植后环磷酰胺用于高危急性髓系白血病和骨髓增生异常综合征患者的单倍体相合异基因造血干细胞移植
Curr Res Transl Med. 2023 Jan-Mar;71(1):103360. doi: 10.1016/j.retram.2022.103360. Epub 2022 Aug 2.
6
Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations.移植后环磷酰胺和胸腺球蛋白在同胞供体外周血造血干细胞移植中的移植物抗宿主病预防作用。
Cell Transplant. 2020 Jan-Dec;29:963689720965900. doi: 10.1177/0963689720965900.
7
Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.单倍体外周血干细胞移植联合移植后环磷酰胺（PTCy）和抗胸腺细胞球蛋白（ATG）与异基因供体移植治疗急性髓系白血病的疗效比较：一项回顾性 10 年研究。
Leuk Res. 2022 Sep;120:106918. doi: 10.1016/j.leukres.2022.106918. Epub 2022 Jul 12.
8
Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.异基因外周血造血干细胞移植中移植后环磷酰胺和抗胸腺细胞球蛋白与环磷酰胺预防移植物抗宿主病的比较：T 细胞和 NK 效应细胞重建的比较。
J Immunol. 2020 Sep 1;205(5):1441-1448. doi: 10.4049/jimmunol.2000578. Epub 2020 Aug 3.
9
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.降低强度预处理方案联合抗胸腺细胞球蛋白和移植后环磷酰胺预防移植物抗宿主病在血缘单倍体造血干细胞移植治疗血液系统恶性肿瘤中的应用。
Biol Blood Marrow Transplant. 2018 Nov;24(11):2259-2264. doi: 10.1016/j.bbmt.2018.07.008. Epub 2018 Aug 7.
10
Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.移植后环磷酰胺联合抗胸腺细胞球蛋白预防移植物抗宿主病可提高老年患者异基因造血细胞移植的生存率并降低非复发死亡率。
Ann Hematol. 2020 Jun;99(6):1377-1387. doi: 10.1007/s00277-020-04033-2. Epub 2020 May 7.

本文引用的文献

1
Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.氟达拉滨和抗胸腺细胞球蛋白预处理方案联合移植后环磷酰胺用于高危急性髓系白血病和骨髓增生异常综合征患者的单倍体相合异基因造血干细胞移植
Curr Res Transl Med. 2023 Jan-Mar;71(1):103360. doi: 10.1016/j.retram.2022.103360. Epub 2022 Aug 2.
2
Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning.免疫谱分析和机器学习揭示移植后环磷酰胺治疗后移植物抗宿主病和复发的特征。
Blood. 2022 Jan 27;139(4):608-623. doi: 10.1182/blood.2021013054.
3
Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.血液恶性肿瘤患者疾病风险分层系统的开发和验证：欧洲血液和骨髓移植学会注册中心的回顾性队列研究。
Lancet Haematol. 2021 Mar;8(3):e205-e215. doi: 10.1016/S2352-3026(20)30394-X.
4
Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.异基因外周血造血干细胞移植中移植后环磷酰胺和抗胸腺细胞球蛋白与环磷酰胺预防移植物抗宿主病的比较：T 细胞和 NK 效应细胞重建的比较。
J Immunol. 2020 Sep 1;205(5):1441-1448. doi: 10.4049/jimmunol.2000578. Epub 2020 Aug 3.
5
Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation.在单倍体造血干细胞移植中添加抗胸腺细胞球蛋白对移植后环磷酰胺的影响。
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):617-623. doi: 10.1016/j.clml.2020.04.003. Epub 2020 Apr 20.
6
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies.在患有髓系恶性肿瘤的成人中，采用基于氯法拉滨的低强度预处理方案、外周血干细胞移植及移植后环磷酰胺治疗。
Oncotarget. 2018 Sep 11;9(71):33528-33535. doi: 10.18632/oncotarget.26083.
7
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？反对观点。
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
8
Resilience, health, and quality of life among long-term survivors of hematopoietic cell transplantation.造血细胞移植长期幸存者的恢复力、健康状况和生活质量
Cancer. 2015 Dec 1;121(23):4250-7. doi: 10.1002/cncr.29651. Epub 2015 Aug 19.
9
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.非清髓性 HLA 单倍型相合异基因骨髓移植联合大剂量移植后环磷酰胺的风险分层结局
Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.
10
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后无移植物抗宿主病、无复发生存的复合终点
Blood. 2015 Feb 19;125(8):1333-8. doi: 10.1182/blood-2014-10-609032. Epub 2015 Jan 15.